Patents Assigned to QILU Pharmaceutical Co., Ltd.
-
Publication number: 20230219986Abstract: The present invention provides a novel aminopyrimidine compound as a fourth-generation EGFR (T790M/C797S mutation) selective inhibitor, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compound, and a method for treating a cell proliferative disease, such as a cancer, by using the compound of the present invention.Type: ApplicationFiled: March 19, 2021Publication date: July 13, 2023Applicants: QILU PHARMACEUTICAL CO., LTD., QILU PHARMACEUTICAL CO., LTD.Inventors: Wei DENG, Shansong ZHENG, Sebastien Andre CAMPOS, Yingying YANG, Zhenhua TIAN, Qingmei ZHENG, Guosheng WU, Zhiwei ZHAO, Leilei LI, Jianmin FU, Shuyong ZHAO
-
Publication number: 20220411492Abstract: Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.Type: ApplicationFiled: May 15, 2020Publication date: December 29, 2022Applicant: QILU PHARMACEUTICAL CO., LTD.Inventors: Yingying YANG, Gao LI, Yaning WANG, Zhenming AN, Shuyong ZHAO, Yuxue LIU, Shicong LIU, Meijuan ZHANG, Jinjin JIANG
-
Patent number: 11180501Abstract: Disclosed in the present disclosure are a crystal form of a ?-lactamase inhibitor and a preparation method therefor, as well as an application of the crystal form in preparing a ?-lactamase inhibitor drug.Type: GrantFiled: December 3, 2018Date of Patent: November 23, 2021Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Cheng Li, Zhigang Huang, Charles Z. Ding, Weidong Li
-
Patent number: 10738051Abstract: Disclosed in the present invention is a type of novel ?-lactamase inhibitors, and specifically disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 2, 2017Date of Patent: August 11, 2020Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Boyu Hu, Charles Z. Ding, Zhigang Huang, Ruibin Lin, Minliang Xiao, Jinsheng Xie, Shuhui Chen, Cheng Li
-
Patent number: 10662198Abstract: The present disclosure relates to polymorphic forms of the compound methyl (3R,6S)-6-amino-sulfonylamino-1-(thiazol-2-yl)-3-(2,3,4-trifluorophenyl)-3,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-4-formate (compound 1). The present disclosure further relates to a pharmaceutical composition and pharmaceutical use and a preparation method of the polymorphic forms of compound 1.Type: GrantFiled: April 26, 2018Date of Patent: May 26, 2020Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Jianwei Shen, Jin Zhang, Long Li, Yonghong Gao, Zhantao Zhang, Yong Zhang
-
Patent number: 10253030Abstract: Disclosed in the present disclosure are a crystal form of a dihydropyrido ring compound, and preparation method and intermediate thereof.Type: GrantFiled: November 2, 2016Date of Patent: April 9, 2019Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Haiying He, Kai Zhou, Xiaolin Li, Xiaofei Wang, Dakun Qin, Xingxing Wang, Feifei Yang, Zheng Wang, Zongbin Li
-
Patent number: 10053477Abstract: Disclosed is a spirocyclic aryl phosphorus oxide or sulfide as an ALK inhibitor, particularly, a compound represented by formula (I) as an ALK inhibitor or pharmaceutically acceptable salt thereof.Type: GrantFiled: June 29, 2015Date of Patent: August 21, 2018Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Zhaozhong Ding, Minghui Zhang, Shuhui Chen, Xile Liu, Yidong Zhu, Chuanwen Fan, Baoping Zhao, Long Zhang, Yingying Yang, Qingmei Zheng, Shansong Zheng, Haiwen Wan, Jinqing Hu
-
Patent number: 9938301Abstract: Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 27, 2015Date of Patent: April 10, 2018Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Haiying He, Kai Zhou, Hua Qin, Xiaolin Li, Yuedong Zhou, Xiaofei Wang, Xuemei Chi, Jian Li, Shuhui Chen
-
Patent number: 8916574Abstract: The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.Type: GrantFiled: September 20, 2010Date of Patent: December 23, 2014Assignee: Qilu Pharmaceutical Co., Ltd.Inventors: Jingyi Wang, Chuanwen Fan, Long Zhang, Zhongru Guo, Ying Li, Shaobo Yang, Shousheng Yan, Jianrong Zhu, Qingmin Yang, Minghui Zhang
-
Patent number: 8637681Abstract: Provided are pyrrolyl substituted dihydroindol-2-one derivatives represented by formula (I), pharmaceutically acceptable salts or solvates of said derivatives, or solvates of said salts, which are effective tyrosine kinase inhibitors. Also provided are the preparation methods of the above compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in manufacturing drugs useful for the treatment or adjunctive treatment of tumors medicated by tyrosine kinases or proliferation or migration of tumor cells driven by tyrosine kinases in mammals (including human).Type: GrantFiled: March 31, 2011Date of Patent: January 28, 2014Assignee: Qilu Pharmaceutical Co., Ltd.Inventors: Jingyi Wang, Chuanwen Fan, Long Zhang, Boyan Xu, Shousheng Yan, Zongru Guo, Minghui Zhang, Dong Lin, Zhantao Zhang, Haojie Zhou
-
Publication number: 20130158030Abstract: Provided are pyrrolyl substituted dihydroindol-2-one derivatives represented by formula (I), pharmaceutically acceptable salts or solvates of said derivatives, or solvates of said salts, which are effective tyrosine kinase inhibitors. Also provided are the preparation methods of the above compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in manufacturing drugs useful for the treatment or adjunctive treatment of tumors medicated by tyrosine kinases or proliferation or migration of tumor cells driven by tyrosine kinases in mammals (including human).Type: ApplicationFiled: March 31, 2011Publication date: June 20, 2013Applicant: QILU PHARMACEUTICAL CO., LTDInventors: Jingyi Wang, Chuanwen Fan, Long Zhang, Boyan Xu, Shousheng Yan, Zongru Guo, Minghui Zhang, Dong Lin, Zhantao Zhang, Haojie Zhou
-
Publication number: 20120301547Abstract: A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.Type: ApplicationFiled: November 22, 2010Publication date: November 29, 2012Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, QILU PHARMACEUTICAL CO., LTD.Inventors: Yong Gan, Chunliu Zhu, Qingmin Yang, Jingyi Wang, Xiaoqing Zheng, Li Gan, Xinxin Zhang
-
Publication number: 20120208833Abstract: The present invention relates to 4-(substituted anilino)-quinazoline derivatives as tyrosine kinase inhibitors. Specifically, compounds of formula I, or pharmaceutically acceptable salts or solvates thereof are disclosed, in which each substitutent in formula I is defined in the description. Preparation method of the compounds of formula I, pharmaceutical compositions and pharmaceutical uses thereof are also disclosed. The compounds of formula I are effective tyrosine kinase inhibitors.Type: ApplicationFiled: September 20, 2010Publication date: August 16, 2012Applicant: QILU Pharmaceutical Co., Ltd.Inventors: Jingyi Wang, Chuanwen Fan, Long Zhang, Zhongru Guo, Ying Li, Shaobo Yang, Shousheng Yan, Jianrong Zhu, Qingmin Yang, Minghui Zhang